European Journal of Heart Failure最新文献

{"title":"Reply to the letter regarding the article 'Lower extremity lymphatic flow is associated with diuretic response in acute heart failure'.","authors":"Barbara Ponikowska,Jan Biegus","doi":"10.1002/ejhf.3690","DOIUrl":"https://doi.org/10.1002/ejhf.3690","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"3 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143932834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of arrhythmia-induced cardiomyopathy using magnetic resonance imaging in patients with persistent atrial fibrillation and left ventricular systolic dysfunction - insights from DECAAF II.","authors":"Ala Assaf,Han Feng,Mayana Bsoul,Ghassan Bidaoui,Hadi Younes,Christian Massad,Mario Mekhael,Charbel Noujaim,Omar Kreidieh,Swati Rao,Amitabh Pandey,Philipp Sommer,Christian Mahnkopf,Nassir Marrouche,Christian Sohns","doi":"10.1002/ejhf.3684","DOIUrl":"https://doi.org/10.1002/ejhf.3684","url":null,"abstract":"AIMSAtrial fibrillation (AF) ablation in heart failure reduces mortality and hospitalizations and improves ejection fraction. Arrhythmia-induced cardiomyopathy (AIC) is diagnosed after complete recovery of left ventricular systolic function after ablation. We aimed to identify the prevalence and pre-ablation predictors of AIC among patients with AF and left ventricular systolic dysfunction (LVSD).METHODS AND RESULTSWe utilized the DECAAF II database, where 815 patients with persistent AF underwent late gadolinium enhancement cardiac magnetic-resonance imaging (LGE-CMR) before and 3 months after AF ablation. We only included patients with available left ventricular ejection fraction (LVEF) and LVSD. AF burden was continuously monitored. AIC was defined as LVSD and coexisting AF in patients with ejection fraction improvement to ≥50% following ablation. We identified 119 patients with LVSD and AF with a mean LVEF of 39.1 ± 7.8% and mean baseline fibrosis of 20.0 ± 7.3%. Mean AF burden post-ablation was 16.8 ± 20.2%, and mean LVEF recovery was 13.9 percentage points. Seventy-two patients (60.5%) fulfilled the criteria for AIC, and 47 (39.5%) did not. AIC patients had a mean baseline LVEF of 39.1 ± 7.9% (vs. 39.2 ± 7.9% in non-AIC patients; p = 0.9), a significantly lower percentage of fibrosis in the left atrial septal wall (12.2 ± 10.0% vs. 20.7 ± 11.4% in non-AIC patients, p < 0.001). Additionally, LVEF improvement was correlated with lower AF burden post-ablation (r = -0.23, p = 0.02).CONCLUSIONSIn this post-hoc analysis of the DECAAF II trial, we found that the majority of patients with LVSD and persistent AF have AIC rather than primary cardiomyopathy. We identified LGE-CMR as a differentiator between AIC and other cardiomyopathies.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"142 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143945164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Further considers on the FINEARTS-HF trial.","authors":"Chang Liu,Min Cao","doi":"10.1002/ejhf.3689","DOIUrl":"https://doi.org/10.1002/ejhf.3689","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"44 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143932833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to 'Further considerations on the FINEARTS-HF trial'.","authors":"Jawad H Butt,John J V McMurray","doi":"10.1002/ejhf.3688","DOIUrl":"https://doi.org/10.1002/ejhf.3688","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"19 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143932836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing heart failure after surgical occlusion of the left atrial appendage. Letter regarding the article ‘Heart failure after left atrial appendage occlusion: Insights from the LAAOS III randomized trial’","authors":"Claudia Stöllberger, Josef Finsterer, Birke Schneider","doi":"10.1002/ejhf.3663","DOIUrl":"https://doi.org/10.1002/ejhf.3663","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"28 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143927262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Donor heart allocation systems in Europe. A scientific statement of the Heart Failure Association of the ESC","authors":"Hoong Sern Lim, Kevin Damman, Guillaume Baudry, Maja Cikes, Stamatis Adamopoulos, Tuvia Ben‐Gal, Nicolas Girerd, Andreas Zuckermann, Marco Masetti, Sanem Nalbantgil, Laurens Tops, Piotr Ponikowski, Maria Crespo‐Leiro, Frank Ruschitzka, Marco Metra, Finn Gustafsson","doi":"10.1002/ejhf.3681","DOIUrl":"https://doi.org/10.1002/ejhf.3681","url":null,"abstract":"Heart transplantation remains the gold standard for treatment of most patients with advanced heart failure (HF), but despite improvements of organ recovery and utilization, donor heart scarcity remains a critically limiting factor. Detailed heart allocation systems (HASs) are in place to ensure use of organs for appropriate candidates, In Europe multiple, different HASs have evolved in different countries or communities of collaborating countries, like Eurotransplant or Scandiatransplant. In this scientific statement, we review the generic ethical and practical principles underlying allocation principles and examine and describe different European HASs with the purpose of discussing impact of outcomes for patients with advanced HF. It is shown that European HASs differ significantly with respect to which patients are prioritized and the methods by which the prioritization is performed. It is argued that the most commonly used parameter to describe success of a HAS, namely 1‐year survival after heart transplantation, is a poor metric of HAS performance. The impact of HASs should be evaluated by several measures such as survival from listing, time to transplantation, the characteristics of patients undergoing heart transplantation, and over a longer time interval to understand the balance of early and late post‐transplant risks and benefit. Mapping European HASs is a step towards understanding these factors and further research should determine the optimal HAS in a given HF population at a given time.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"228 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143920218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aetiological phenotypes of atrial and ventricular secondary tricuspid regurgitation and their prognostic implications: insights from the CARE‐TR registry","authors":"Laura Lupi, Elena Antonioli, Angelica Praderio, Alessandro Villaschi, Elisa Soranzo, Nicola Saccani, Kamil Stankowski, Daniele Cocianni, Beniamino Pagliaro, Valeria Magni, Marco Loffi, Daniela Tomasoni, Matteo Pagnesi, Antonio Mangieri, Davide Stolfo, Gianfranco Sinagra, Marianna Adamo, Marco Metra","doi":"10.1002/ejhf.3678","DOIUrl":"https://doi.org/10.1002/ejhf.3678","url":null,"abstract":"AimsTo report prevalence and clinical outcomes of different aetiological phenotypes of atrial and ventricular secondary tricuspid regurgitation (ASTR/VSTR).Methods and resultsThe Consecutive pAtients with seveRE Tricuspid Regurgitation evaluated in Heart Failure (HF) and Valve Clinics (CARE‐TR) registry collected data from patients with at least severe tricuspid regurgitation (TR) enrolled at three Italian centres. The present analysis includes 648 patients with secondary TR, 22.1% with ASTR and 77.9% with VSTR. Patients with ASTR were further stratified in those with atrial fibrillation (AF, 25.2%), HF with preserved ejection fraction (HFpEF, 37.8%), and both (37.0%). Patients with VSTR were subdivided into those with severe left‐sided valvular heart disease (LS‐VHD, 28.5%), HF with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF, 29.1%), HFpEF (35.5%), pre‐capillary pulmonary hypertension (PH, 4.0%) and isolated right ventricular dysfunction (RVD, 2.9%). After a median follow‐up of 498 days, 118 (18.2%) patients died and 153 (23.6%) were hospitalized for HF. Two‐year survival free from the composite outcome of death or HF hospitalization was higher in patients with ASTR compared with those with VSTR (73.5% vs. 54.4%; <jats:italic>p</jats:italic> &lt; 0.001). After adjustment for variables related with HF severity, VSTR remained independently associated with an increased risk of events (adjusted hazard ratio 2.00; 95% confidence interval 1.33–3.02; <jats:italic>p</jats:italic> = 0.001). Among ASTR patients, combined AF and HFpEF was associated with a poorer outcome compared with AF or HFpEF alone (60.2% vs. 80.5% vs. 83.6%; <jats:italic>p</jats:italic> = 0.022). Among patients with VSTR, overall survival free from the composite outcome was 85%, 65%, 54%, 39% and 38% for RVD, HFpEF, HFrEF/HFmrEF, severe LS‐VHD, and pre‐capillary PH, respectively (<jats:italic>p</jats:italic> &lt; 0.001).ConclusionsIn a real‐world population with at least severe secondary TR, 22% had ASTR and showed better outcomes as compared to VSTR. Among patients with ASTR, combination of AF and HFpEF was common and associated with the worst prognosis. Among patients with VSTR, those with pre‐capillary PH had the poorest outcomes, followed by those with LS‐VHD.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"3 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143920170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to 'Assessing heart failure after surgical occlusion of the left atrial appendage'.","authors":"Philipp Krisai,Richard P Whitlock,Jeff S Healey,","doi":"10.1002/ejhf.3666","DOIUrl":"https://doi.org/10.1002/ejhf.3666","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"30 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143932470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heart failure and obesity: Translational approaches and therapeutic perspectives. A scientific statement of the Heart Failure Association of the ESC.","authors":"Gianluigi Savarese,Gabriele G Schiattarella,Felix Lindberg,Markus S Anker,Antoni Bayes-Genis,Magnus Bäck,Frieder Braunschweig,Chiara Bucciarelli-Ducci,Javed Butler,Antonio Cannata,Federico Capone,Ovidiu Chioncel,Emilia D'Elia,Arantxa González,Gerasimos Filippatos,Nicolas Girerd,Jean-Sébastien Hulot,Carolyn S P Lam,Lars H Lund,Christoph Maack,Brenda Moura,Mark C Petrie,Massimo Piepoli,Abdullah Shehab,Mehmet B Yilmaz,Peter Seferovic,Carlo G Tocchetti,Giuseppe M C Rosano,Marco Metra","doi":"10.1002/ejhf.3676","DOIUrl":"https://doi.org/10.1002/ejhf.3676","url":null,"abstract":"Obesity and heart failure (HF) represent two growing pandemics. In the general population, obesity affects one in eight adults and is linked with an increased risk for HF. Obesity is even more common in patients with HF, where it complicates the diagnosis of HF and is linked with worse symptoms and impaired exercise capacity. Over the past few years, new evidence on the mechanisms linking obesity with HF has been reported, particularly in relation to HF with preserved ejection fraction. Novel therapies inducing weight loss appear to have favourable effects on health status and cardiovascular risk. Against the backdrop of this rapidly evolving evidence landscape, HF clinicians are increasingly required to tailor their preventive, diagnostic, and therapeutic approaches to HF in the presence of obesity. This scientific statement by the Heart Failure Association of the European Society of Cardiology provides an up-to-date summary on obesity in HF, covering key areas such as epidemiology, translational aspects, diagnostic challenges, therapeutic approaches, and trial design.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"101 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143915150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Residual tricuspid regurgitation after tricuspid valve interventions: What do we know?","authors":"Lukas Stolz, Charles Davidson, Volker Rudolph, Jörg Hausleiter","doi":"10.1002/ejhf.3675","DOIUrl":"https://doi.org/10.1002/ejhf.3675","url":null,"abstract":"<h2> Introduction</h2>\u0000<p>Tricuspid regurgitation (TR) is a major health burden being associated with substantial morbidity, mortality and quality of life (QoL) impairment.<span>¹</span> Advancements in transcatheter tricuspid valve interventions (TTVI) have significantly changed the landscape of tricuspid valve (TV) disease enabling treatment of elderly patients at advanced or prohibitive surgical risk. TV transcatheter edge-to-edge repair (T-TEER) is the most commonly used treatment technique which has shown QoL improvement beyond medical treatment in randomized controlled settings.<span>^{2, 3}</span> Due to advancements in transcatheter TV replacement (TTVR)<span>^4-8</span> which is able to almost completely eliminate TR, a debate has arisen about how much TR reduction is desirable, safe and necessary.</p>\u0000<p>Over the past months and years, the body of evidence on this question has become more substantial. In this viewpoint, we therefore present our perspective on the topic based on the data available today.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"137 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143910850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}